Limits...
Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.

Khanna S, Das A, Spieldenner J, Rink C, Roy S - J Med Food (2015)

Bottom Line: Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits.Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation.In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA .

ABSTRACT
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.

Show MeSH

Related in: MedlinePlus

CAPROS® supplementation decreased calculated blood LDL cholesterol and total cholesterol/HDL in overweight/Class-1 obese human subjects. Healthy human subjects were orally supplemented for 12 weeks with CAPROS (500 mg/b.i.d) followed by 2 weeks of washout. Lipid profile was measured in fasting plasma. Calculated LDL cholesterol concentrations plotted individual (A) and mean (B). Total cholesterol/HDL plotted individual (C) and mean (D). Values are mean±SEM (n=9). *denotes P<.05 compared to baseline. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4390209&req=5

f1: CAPROS® supplementation decreased calculated blood LDL cholesterol and total cholesterol/HDL in overweight/Class-1 obese human subjects. Healthy human subjects were orally supplemented for 12 weeks with CAPROS (500 mg/b.i.d) followed by 2 weeks of washout. Lipid profile was measured in fasting plasma. Calculated LDL cholesterol concentrations plotted individual (A) and mean (B). Total cholesterol/HDL plotted individual (C) and mean (D). Values are mean±SEM (n=9). *denotes P<.05 compared to baseline. HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Mentions: Fasting lipid profile measurements demonstrated a significant decrease (P=.023) in the calculated LDL-C concentration following 12 weeks of supplementation compared to the concentrations observed during averaged baseline visits (Fig. 1 and Table 2). Additionally, a highly significant (P=.006) reduction in total cholesterol/HDL was also noted following 12 weeks of CAPROS supplementation (Fig. 1). The concentration of CRP increases when there is systemic inflammation.15 A high concentration of CRP is considered a risk factor for heart disease.15 A more sensitive CRP test, called a hs-CRP assay, is a promising marker of coronary heart disease.16 Although a trend of decreased plasma CRP levels was observed following 12 weeks of supplementation, the effect did not reach significance (P=.107). However, a highly significant (P<.001) reduction in the hs-CRP levels was noted 12 weeks post-supplementation compared to baseline (Fig. 2).


Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.

Khanna S, Das A, Spieldenner J, Rink C, Roy S - J Med Food (2015)

CAPROS® supplementation decreased calculated blood LDL cholesterol and total cholesterol/HDL in overweight/Class-1 obese human subjects. Healthy human subjects were orally supplemented for 12 weeks with CAPROS (500 mg/b.i.d) followed by 2 weeks of washout. Lipid profile was measured in fasting plasma. Calculated LDL cholesterol concentrations plotted individual (A) and mean (B). Total cholesterol/HDL plotted individual (C) and mean (D). Values are mean±SEM (n=9). *denotes P<.05 compared to baseline. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4390209&req=5

f1: CAPROS® supplementation decreased calculated blood LDL cholesterol and total cholesterol/HDL in overweight/Class-1 obese human subjects. Healthy human subjects were orally supplemented for 12 weeks with CAPROS (500 mg/b.i.d) followed by 2 weeks of washout. Lipid profile was measured in fasting plasma. Calculated LDL cholesterol concentrations plotted individual (A) and mean (B). Total cholesterol/HDL plotted individual (C) and mean (D). Values are mean±SEM (n=9). *denotes P<.05 compared to baseline. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Mentions: Fasting lipid profile measurements demonstrated a significant decrease (P=.023) in the calculated LDL-C concentration following 12 weeks of supplementation compared to the concentrations observed during averaged baseline visits (Fig. 1 and Table 2). Additionally, a highly significant (P=.006) reduction in total cholesterol/HDL was also noted following 12 weeks of CAPROS supplementation (Fig. 1). The concentration of CRP increases when there is systemic inflammation.15 A high concentration of CRP is considered a risk factor for heart disease.15 A more sensitive CRP test, called a hs-CRP assay, is a promising marker of coronary heart disease.16 Although a trend of decreased plasma CRP levels was observed following 12 weeks of supplementation, the effect did not reach significance (P=.107). However, a highly significant (P<.001) reduction in the hs-CRP levels was noted 12 weeks post-supplementation compared to baseline (Fig. 2).

Bottom Line: Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits.Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation.In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA .

ABSTRACT
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.

Show MeSH
Related in: MedlinePlus